Overall, our findings directly in BC patients emphasize the use of TERT, PD-L1, PD-L2, miR-138-5p, and miR-100-5p as diagnosis and prognosis biomarkers for patients’ stratification and follow-up. This evidence concerns the gene TERT and breast cancer.